UC San Diego to Advance Stem Cell Therapies in New Space Station Lab – UC San Diego Health
stemadminStem Cell MedicineNo comments

A three-year, nearly $5 million award from NASA will allow researchers at the Sanford Stem Cell Clinical Center at UC San Diego Health, Sanford Consortium for Regenerative Medicine and their partners at Space Tango to develop a new integrated space stem cell orbital research laboratory within the International Space Station (ISS) and launch three collaborative research projects within it. Stem cells self-renew, generating more stem cells, and specialize into tissue-specific cells, such as blood, brain and liver cells, making them ideal for biological studies far from Earths resources

Read more
Stem-cell therapy – Wikipedia
stemadminStem Cell MedicineNo comments

Use of stem cells to treat or prevent a disease or condition Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition.[1] As of 2016[update], the only established therapy using stem cells is hematopoietic stem cell transplantation (HSCT).[2] This usually takes the form of a bone marrow transplantation, but the cells can also be derived from umbilical cord blood. Research is underway to develop various sources for stem cells as well as to apply stem-cell treatments for neurodegenerative diseases[3] and conditions such as diabetes and heart disease

Read more
CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19) – GlobeNewswire
stemadminStem Cell MedicineNo comments

NEW YORK and AUSTIN, Texas, April 07, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics (Cytovia), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer and infectious diseases, announced today that it is expanding its programs to help urgently address the current SAR CoV2 (COVID-19) crisis. Natural Killer cells are a first line of defense not only against tumor cells but also against severe acute infectious diseases. Using a bi-functional approach has the potential to minimize virus escape from the immune response thereby inhibiting the intensification of the inflammation leading to Acute Respiratory Syndrome (ARS).

Read more
Celularity Expands Strategic Collaboration with United Therapeutics Corporation to COVID-19 Infection and Acute Respiratory Distress Syndrome – The…
stemadminStem Cell MedicineNo comments

WARREN, N.J., April 9, 2020 /PRNewswire/ --Celularity Inc. ("Celularity" or the "Company"), a clinical-stage company developing allogeneic cellular therapies from human placentas, today announced the expansion of its existing collaborative license agreement with United Therapeutics Corporation's (Nasdaq: UTHR) wholly-owned subsidiary, Lung Biotechnology PBC, to include the treatment of COVID-19 and Acute Respiratory Distress Syndrome (ARDS).

Read more
Unproven Stem Cell Therapy Gets OK for Testing in Coronavirus Patients – The New York Times
stemadminStem Cell MedicineNo comments

At least one outside expert said the approach could present safety risks. Paul Knoepfler, a stem cell researcher at the University of California, Davis, said that patients with coronavirus can develop severe reactions where their immune systems go too far in attacking cells in their lungs, causing damaging inflammation. Other cell therapies tested in China are designed to dampen the immune response

Read more
What You Need to Know About the FDA’s Approval of Opdivo-Yervoy for Hepatocellular Carcinoma – Curetoday.com
stemadminStem Cell MedicineNo comments

The Food and Drug Administration approved the dual immunotherapy of Opdivo and Yervoy for the treatment of patients with advanced hepatocellular carcinoma. Heres what you need to know. This is the only dual immunotherapy approved by the FDA in this setting of patients with HCC and was based on the results of the phase 1/2 CheckMate-040 trial

Read more
Mesoblast’s remestemcel-L receives FDA IND clearance for treating COVID-19 patients with acute respiratory distress – Small Caps
stemadminStem Cell MedicineNo comments

Regenerative medicine company Mesoblast (ASX: MSB) has received US Food and Drug Administration Investigational New Drug (IND) clearance for its remestemcel-L treatment to be used in COVID-19 patients presenting with acute respiratory distress syndrome. According to Mesoblast chief medical officer Dr Fred Grossman, the FDA IND approval now enables US-based COVID-19 patients with poor prognosis to be treated with remestemcel-L under compassionate usage grounds and in a planned randomised controlled trial.

Read more
COVID-19 Tips for Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia – Curetoday.com
stemadminStem Cell MedicineNo comments

The COVID-19 pandemic has created a unique challenge for patients with myelodysplastic syndromes and acute myeloid leukemia, creating many questions that experts tried to answer in a recent webinar from The Aplastic Anemia and MDS International Foundation. The Aplastic Anemia and MDS International Foundation (AAMDSIF) recently hosted a webinar to address the questions of this patient population by connecting them with Dr. Gail J.

Read more

Theme: Illdy.